camptothecin has been researched along with Cancer of Head in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (16.67) | 18.2507 |
| 2000's | 25 (59.52) | 29.6817 |
| 2010's | 9 (21.43) | 24.3611 |
| 2020's | 1 (2.38) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, B; Deng, H; Gu, S; Li, Y; Lin, C; Shen, Z; Wei, Z | 1 |
| Nanbu, K; Nanbu, T; Ohkoshi, E; Sakagami, H; Shimada, J; Umemura, N | 1 |
| Cooper, RC; Gui, Q; He, H; Wang, J; Yang, H | 1 |
| Komune, S; Nakashima, T; Toh, S; Yamauchi, M; Yasumatsu, R | 1 |
| Chang, PM; Chen, SC; Yang, MH | 1 |
| Fukushima, K; Ikeda, JI; Kasama, T; Kato, Y; Miura, D; Morii, E; Naito, Y; Nishikawa, Y; Nojima, H; Ohno, S; Okuzaki, D; Ota, K; Sasakura, T; Torigata, K; Uchihashi, T; Wang, M; Yabuta, N | 1 |
| Dahlstrom, KR; Gao, F; Han, P; Li, G; Liu, H; Liu, Z; Owzar, K; Sturgis, EM; Wei, Q; Zevallos, JP | 1 |
| Davies, A; Gandara, D; Huynh, M; Johl, J; Lara, P; Lau, D; Tanaka, M | 1 |
| Bhattacharya, A; Cao, S; Chintala, S; Durrani, FA; Rustum, YM; Slocum, HK; Tóth, K | 1 |
| Enomoto, T; Fukutsuji, K; Ikeda, H; Kitano, H; Morizane, R; Nakahara, K; Nosaka, A; Sakoda, T; Shibano, A; Yamanishi, M | 1 |
| Argiris, A; Axelrod, R; Brockstein, B; Buchanan, A; Forastiere, A; Ghebremichael, M; Hahn, K; Kolesar, J; Pins, M | 1 |
| Cao, S; Chintala, S; Durrani, FA; Jensen, RL; Rustum, YM; Tóth, K; Vaughan, MM | 1 |
| Bhattacharya, A; Cao, S; Chintala, S; Dean, R; Durrani, FA; Ola, MS; Rustum, YM; Slocum, HK; Smith, SB; Tóth, K; Yin, MB; Zinia, TR | 1 |
| Argiris, A; Arun, P; Feldman, LE; Forastiere, AA; Gilbert, J; Haigentz, M; Jang, M; Lee, JW; Van Waes, C | 1 |
| Abad, A; Barnadas, A; Font, A; Guillot, M; Manzano, JL; Margeli, M; Martinez, E; Rosell, R; Sanchez, JM; Taron, M | 1 |
| Frank, C; Hapke, G; Rustum, YM; Wu, J; Yin, MB | 1 |
| Needle, MN | 1 |
| Azrak, RG; Cao, S; Durrani, FA; McLeod, HL; Pendyala, L; Rustum, YM; Slocum, HK; Tóth, K; Yin, MB; Zhang, W | 1 |
| Humblet, Y | 1 |
| Hanazono, Y; Ichimura, K; Kanazawa, T; Kitamura, K; Kume, A; Mizukami, H; Nishino, H; Okada, T; Ozawa, K | 1 |
| Baron, B; Bloch, J; Borner, M; Chollet, P; Degardin, M; Dittrich, C; Duffaud, F; Fumoleau, P; Lacombe, D; Rolland, F; Vermorken, JB | 1 |
| Azrak, R; Bhattacharya, A; Cao, S; Durrani, FA; Mazurchuk, R; Pendyala, L; Rustum, YM; Slocum, HK; Spernyak, JA; Tóth, K | 1 |
| Murphy, BA | 1 |
| Azrak, RG; Cao, S; Durrani, FA; Li, X; McLeod, HL; Pendyala, L; Rustum, YM; Shannon, WD; Smith, PF; Yu, J | 1 |
| Brodsky, I; Rosenbluth, JZ; Styler, MJ; Zak, D | 1 |
| Chmura, SJ; Haraf, DJ; Kao, J; Milano, MT; Salama, JK; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Azrak, RG; Bhattacharya, A; Cao, S; Durrani, FA; Frank, C; Hapke, G; Li, ZR; Rustum, YM; Tóth, K; Yin, MB | 1 |
| Chu, E; Vokes, EE | 1 |
| Caponigro, F; Cartenì, G; Davis, WB; Droz, JP; Milano, A; Pollard, P | 1 |
| Aulino, JM; Burkey, BB; Chung, CH; Cmelak, A; Gilbert, J; Murphy, BA; Netterville, J; Shyr, Y; Sinard, RJ; Yarbrough, WG | 1 |
| Ara, G; Boscia, RE; Holden, SA; Korbut, T; Teicher, BA | 1 |
| Heuser, A; Sauer, R | 1 |
| Ensley, JF; Lew, D; Rodriguez, GI; Schuller, D; Smith, RE; Taylor, SA | 1 |
| Robert, F; Soong, SJ; Wheeler, RH | 1 |
| Lad, TE; Minami, H; Nicholas, MK; Ratain, MJ; Vokes, EE | 1 |
| Chen, AY; Choy, H; Rothenberg, ML | 1 |
| Azrak, RG; Cao, S; Guo, B; Rustum, YM; Tóth, K | 1 |
| Azrak, RG; Frank, C; Guo, B; Minderman, H; Rustum, YM; Slocum, HK; Vanhoefer, U; Wrzosek, C; Yin, MB | 1 |
| Arietta, R; Brockstein, B; Keubler, JP; Lad, T; Rosen, F; Sciortino, D; Vokes, E | 1 |
| Prescott, LM | 1 |
| Choy, H; MacRae, R | 1 |
| Burkey, B; Cmelak, A; Douglas, S; Murphy, BA; Netterville, J; Shyr, Y; Smith, W | 1 |
9 review(s) available for camptothecin and Cancer of Head
| Article | Year |
|---|---|
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Eruptions; Drug Hypersensitivity; Drug Interactions; Gemcitabine; Head and Neck Neoplasms; Humans; Irinotecan; Pancreatic Neoplasms | 2002 |
Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck.
Topics: Camptothecin; Carcinoma, Squamous Cell; Clinical Trials as Topic; DNA Topoisomerases, Type I; Head and Neck Neoplasms; Humans; Irinotecan; Neoplasm Recurrence, Local; Topoisomerase I Inhibitors; Topotecan | 2005 |
Combination of gemcitabine and irinotecan for recurrent metastatic osteogenic sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Etoposide; Femoral Neoplasms; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Osteosarcoma; Palliative Care; Salvage Therapy; Scalp; Skin Neoplasms; Thoracotomy | 2005 |
Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Protein-Tyrosine Kinases | 2006 |
[Topoisomerase I inhibitor with potential radiosensitizing effect].
Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Child; Clinical Trials as Topic; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Topoisomerase I Inhibitors; Topotecan | 1997 |
DNA topoisomerase I-targeting drugs as radiation sensitizers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Colonic Neoplasms; Combined Modality Therapy; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Enzyme Inhibitors; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Radiation-Sensitizing Agents; Topotecan | 1999 |
Irinotecan and radiation in combined-modality therapy for solid tumors.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Radiotherapy, Adjuvant; Topoisomerase I Inhibitors; Uterine Cervical Neoplasms | 2001 |
Topoisomerase I inhibitors in the treatment of head and neck cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Enzyme Inhibitors; Head and Neck Neoplasms; Humans; Irinotecan; Survival Analysis; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2001 |
14 trial(s) available for camptothecin and Cancer of Head
| Article | Year |
|---|---|
Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Squamous Cell Carcinoma of Head and Neck; Tegafur; Uracil | 2016 |
Population-based phase I trial of irinotecan and epirubicin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Drug Synergism; Epirubicin; Female; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neutropenia; Topoisomerase I Inhibitors | 2008 |
[Docetaxel (TXT) and irinotecan (CPT-11) as a second-line chemotherapy for platinum-pretreated squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Platinum; Taxoids | 2008 |
Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cyclooxygenase 2; Docetaxel; Drug Administration Schedule; Female; Glucuronosyltransferase; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids; Vascular Endothelial Growth Factor A | 2009 |
Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Squamous Cell; Cytokines; Disease Progression; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; NF-kappa B; Pyrazines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2013 |
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; Drug Administration Schedule; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gene Expression; Genes, erbB-1; Head and Neck Neoplasms; Humans; Immunoglobulin G; Irinotecan; Lung Neoplasms; Male; Mice | 2004 |
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis | 2004 |
Phase II study of rubitecan in recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local | 2008 |
Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local | 2008 |
Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck. A phase II Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Topotecan | 1996 |
A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Quality of Life; Remission Induction; Survival Analysis; Topotecan | 1997 |
Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.
Topics: Adult; Aged; Anticonvulsants; Blood Cell Count; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Glioma; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Logistic Models; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged | 1999 |
Phase II trial of aminocamptothecin (9-AC/DMA) in patients with advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged | 2000 |
20 other study(ies) available for camptothecin and Cancer of Head
| Article | Year |
|---|---|
Neddylation inhibitor MLN4924 sensitizes head and neck squamous carcinoma cells to (S)-10-hydroxycamptothecin.
Topics: Camptothecin; Head and Neck Neoplasms; Humans; Squamous Cell Carcinoma of Head and Neck | 2023 |
Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Gefitinib; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Irinotecan; Lysosomes; Mice; Proteolysis; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2018 |
Drug-Conjugated Dendrimer Hydrogel Enables Sustained Drug Release via a Self-Cleaving Mechanism.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Dendrimers; Drug Liberation; Head and Neck Neoplasms; Humans; Hydrogels; Injections; Male; Mice; Mice, Nude; Polyethylene Glycols; Squamous Cell Carcinoma of Head and Neck; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Extrapulmonary small cell carcinoma in head and neck.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Drug Combinations; Etoposide; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Radiotherapy, Adjuvant; Survival Rate; Tegafur | 2015 |
Comprehensive phenotypic analysis of knockout mice deficient in cyclin G1 and cyclin G2.
Topics: Animals; Camptothecin; Cell Line, Tumor; Cells, Cultured; Checkpoint Kinase 2; Cyclin G1; Cyclin G2; DNA Damage; DNA Repair; Down-Regulation; Fibroblasts; Head and Neck Neoplasms; Mice; Mice, Knockout; Phenotype; Phosphorylation; Radiation, Ionizing | 2016 |
Apoptotic capacity and risk of squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Alcohol Drinking; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Case-Control Studies; Female; Flow Cytometry; Head and Neck Neoplasms; Humans; Lymphocytes; Male; Middle Aged; Odds Ratio; Polymorphism, Genetic; Risk Factors; Smoking; Squamous Cell Carcinoma of Head and Neck; Topoisomerase I Inhibitors | 2017 |
Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cell Differentiation; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cysteine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Forkhead Transcription Factors; Head and Neck Neoplasms; Humans; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Organoselenium Compounds; Selenocysteine; Tirapazamine; Triazines; Xenograft Model Antitumor Assays | 2008 |
Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Squamous Cell; Cell Hypoxia; Cysteine; Drug Delivery Systems; Female; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Mice; Mice, Nude; Organoselenium Compounds; Reactive Oxygen Species; RNA, Small Interfering; Selenocysteine; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Downregulation of cystine transporter xc by irinotecan in human head and neck cancer FaDu xenografts.
Topics: Amino Acid Transport Systems; Animals; Camptothecin; Cell Line, Tumor; Cystine; Down-Regulation; Female; Head and Neck Neoplasms; Humans; Irinotecan; Mice; Mice, Nude; Xenograft Model Antitumor Assays | 2010 |
Phosphorylation of chk1 at serine-345 affected by topoisomerase I poison SN-38.
Topics: 14-3-3 Proteins; Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Phytogenic; Camptothecin; Carrier Proteins; cdc25 Phosphatases; Cell Cycle Proteins; Checkpoint Kinase 1; DNA Damage; DNA Fragmentation; DNA-Binding Proteins; Enzyme Inhibitors; G2 Phase; Head and Neck Neoplasms; Humans; Irinotecan; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Phosphorylation; Protein Kinases; Proto-Oncogene Proteins; Serine; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tyrosine 3-Monooxygenase | 2002 |
Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Immunohistochemistry; Irinotecan; Kinetics; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Reverse Transcriptase Polymerase Chain Reaction; Time Factors | 2004 |
Topoisomerase inhibitors enhance the cytocidal effect of AAV-HSVtk/ganciclovir on head and neck cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Dependovirus; Enzyme Inhibitors; Etoposide; Ganciclovir; Gene Expression; Genes, Transgenic, Suicide; Genetic Therapy; Genetic Vectors; Head and Neck Neoplasms; Humans; Thymidine Kinase; Topoisomerase I Inhibitors | 2004 |
Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Squamous Cell; Cell Differentiation; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hypoxia; Irinotecan; Magnetic Resonance Imaging; Mice; Mice, Nude; Microcirculation; Oxygen; Rats; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Squamous Cell; Cysteine; Female; Head and Neck Neoplasms; Humans; Irinotecan; Mice; Mice, Nude; Organoselenium Compounds; Pharmacogenetics; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Selenocysteine; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Irinotecan; Male; Mandibular Diseases; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Osteoradionecrosis; Paclitaxel; Prognosis; Radiotherapy Dosage; Treatment Failure; Treatment Outcome | 2006 |
Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiog
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Cyclooxygenase 2; Cysteine; Down-Regulation; Female; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Mice; Mice, Nude; Neovascularization, Pathologic; Nitric Oxide Synthase Type II; Organoselenium Compounds; Selenocysteine; Transplantation, Heterologous | 2006 |
Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Survival; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Resistance; Fibrosarcoma; Head and Neck Neoplasms; Humans; Hydrogen-Ion Concentration; Mice; Mice, Inbred C3H; Topotecan; Tumor Cells, Cultured | 1993 |
Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Enzyme Inhibitors; Female; Head and Neck Neoplasms; Humans; Irinotecan; Mice; Mice, Nude; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured | 2000 |
Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350.
Topics: Camptothecin; CDC2 Protein Kinase; Cell Cycle; Cell Cycle Proteins; Cell Division; Checkpoint Kinase 1; Cyclin B; DNA Fragmentation; DNA Topoisomerases, Type I; Electrophoresis, Gel, Pulsed-Field; Head and Neck Neoplasms; Humans; Phosphorylation; Protein Kinases; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2000 |
Highlights of the Eighth European Cancer Conference.
Topics: Amifostine; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Docetaxel; Head and Neck Neoplasms; Humans; Irinotecan; Neoplasms; Paclitaxel; Radiation Injuries; Radiation-Protective Agents; Taxoids; Vinblastine; Vinorelbine | 1995 |